Skip to main navigation

Skip to content

Search for:

About
Technology
Pipeline
Products
- XIPERE®
Investors

Investor Menu

IR Overview
News
Events and Presentations
Governance
SEC Filings
Financial Info
Resources

News

Year

Sep 19 2023

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Aug 14 2023

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2 2023

Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

Aug 1 2023

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

Jul 31 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting

Jul 20 2023

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

Jul 17 2023

Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Jul 11 2023

Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023

Jul 10 2023

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

Jun 1 2023

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Email Alerts
Print Page
RSS Feeds
IR Contact

Request Email Alerts

(678) 270-3631
info@clearsidebio.com
CONTACT US

ABOUT US
MANAGEMENT
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
PRIVACY POLICY

SCIENCE
SUPRACHOROIDAL SPACE
SCS MICROINJECTOR®
PUBLICATIONS & PRESENTATIONS
Intellectual Property

PRODUCTS
XIPERE™

PIPELINE
CLS-AX
INTEGRIN INHIBITOR
GENE THERAPY
COLLABORATIONS

INVESTORS
IR OVERVIEW
NEWS
EVENTS & PRESENTATIONS
GOVERNANCE
SEC FILINGS
FINANCIAL INFO
RESOURCES

Copyright 2023 © Clearside Biomedical | Website Design and Development by Emma Tang Designs